Immunohistochemical Expression of p53, Bcl-2, and Ki-67 Proteins in Traditional Serrated Adenomas of Colon

Jin Hwan Jung; Heon-Ju Kwon; Tae-Jung Kim; Hyung Jun Cho; Hye Kang Kim; Dae Young Cheung; Jin Il Kim; Jae Kwang Kim

doi:10.4166/kjg.2013.62.6.336

Journal List > Korean J Gastroenterol > v.62(6) > 1007171

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jung, Kwon, Kim, Cho, Kim, Cheung, Kim, and Kim: Immunohistochemical Expression of p53, Bcl-2, and Ki-67 Proteins in Traditional Serrated Adenomas of Colon

Original Article

Korean J Gastroenterol 2013;62(6):336-343.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.62.6.336

Immunohistochemical Expression of p53, Bcl-2, and Ki-67 Proteins in Traditional Serrated Adenomas of Colon

Jin Hwan Jung, Heon-Ju Kwon¹, Tae-Jung Kim², Hyung Jun Cho, Hye Kang Kim, Dae Young Cheung, Jin Il Kim, Jae Kwang Kim

Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea

¹Department of Radiology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Hospital Pathology, The Catholic University of Korea, College of Medicine, Seoul, Korea

Correspondence to: Jin Il Kim, Department of Internal Medicine, The Catholic University of Korea, Yeouido St. Mary's Hospital, 10, 63-ro, Yeongdeungpo-gu, Seoul 150-713, Korea. Tel: +82-2-3779-1519, Fax: +82-2-3779-1331, E-mail: jikim@catholic.ac.kr

Received 14 September 2013 Revised 21 October 2013 Accepted 5 November 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background/Aims

Serrated adenomas of the colon show mixed characteristics of both hyperplastic and adenomatous polyps. Serrated adenomas are known to progress via the serrated pathway than the adenoma-carcinoma pathway. The aim of this study was to evaluate the characteristics of traditional serrated adenomas compared to hyperplastic polyps and tubular adenomas by using immunohistochemical staining for p53, Bcl-2, and Ki-67.

Methods

Age, sex, location, size and the immunoexpression of p53, Bcl-2, and Ki-67 were retrospectively analyzed in 20 traditional serrated adenomas, 20 hyperplastic polyps, and 20 tubular adenomas from January 2007 to December 2012 at The Catholic University of Korea, Yeouido St. Mary's Hospital.

Results

There was no difference in Bcl-2 and p53 expression between traditional serrated adenomas and hyperplastic polyps. Ki-67 Expression of traditional serrated adenomas was higher than that of hyperplastic polyps (p=0.001). Ki-67 and p53 expression was similar between traditional serrated and tubular adenomas. Bcl-2 expression of traditional serrated adenomas was lower than that of tubular adenomas (p=0.001). Regarding the expression of p53, Bcl-2, and Ki-67 in traditional serrated adenomas, there were no statistical differences among age, sex, location, and size.

Conclusions

Our study suggested that Ki-67 may be helpful in distinguishing traditional serrated adenomas from hyperplastic polyps, and p53 expression may be ineffective in distinguishing between traditional serrated and tubular adenomas. From Bcl-2 expression, it is suggested that the tumorigenesis of traditional serrated adenomas is lower than that of tubular adenomas.

Go to :

Keywords: Serrated adenoma, p53, Bcl-2, Ki-67

References

1. Mäkinen MJ, George SM, Jernvall P, Mäkelä J, Vihko P, Karttunen TJ. Colorectal carcinoma associated with serrated adenoma–prevalence, histological features, and prognosis. J Pathol. 2001; 193:286–294.

2. Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol. 1990; 14:524–537.

3. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010; 138:2088–2100.

4. Hong SN, Yang DH, Kim YH, et al. MultiSociety Task Force for Development of Guidelines for Colorectal Polyp Screening, Surveillance and Management. Korean guidelines for post-polypectomy colonoscopic surveillance. Korean J Gastroenterol. 2012; 59:99–117.

5. Terdiman JP, McQuaid KR. Surveillance guidelines should be updated to recognize the importance of serrated polyps. Gastroenterology. 2010; 139:1444–1447.

6. Jass JR. Serrated adenoma of the colorectum: a lesion with teeth. Am J Pathol. 2003; 162:705–708.

7. Pap Z, Pávai Z, Dénes L, Brînzaniuc K, Jung I. Hyperplastic polyps and serrated adenomas: precancerous lesions with mixed immunophenotype. Rom J Morphol Embryol. 2011; 52:797–802.

8. Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion' pathway to colorectal cancer. Histopathology. 2006; 49:121–131.

9. Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol. 2005; 124:380–391.

10. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006; 41:185–192.

11. Ozawa A, Konishi F, Fukayama M, Kanazawa K. Apoptosis and its regulation in flat-type early colorectal carcinoma: comparison with that in polypoid-type early colorectal carcinoma. Dis Colon Rectum. 2000; 43(10 Suppl):S23–S28.

12. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol. 1991; 138:807–813.

13. Kaklamanis L, Gatter KC, Mortensen N, et al. p53 expression in colorectal adenomas. Am J Pathol. 1993; 142:87–93.

14. Ladas SD, Kitsanta P, Triantafyllou K, Tzathas C, Spiliadi C, Raptis SA. Cell turnover of serrated adenomas. J Pathol. 2005; 206:62–67.

15. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55:237–241.

16. Popescu RA, Lohri A, de Kant E, et al. bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer. Eur J Cancer. 1998; 34:1268–1273.

17. Sawyer EJ, Cerar A, Hanby AM, et al. Molecular characteristics of serrated adenomas of the colorectum. Gut. 2002; 51:200–206.

18. Hiyama T, Yokozaki H, Shimamoto F, et al. Frequent p53 gene mutations in serrated adenomas of the colorectum. J Pathol. 1998; 186:131–139.

19. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska O, Malecka-Panas E. Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis. 2007; 22:1165–1172.

20. Fujimori Y, Fujimori T, Imura J, et al. An assessment of the diagnostic criteria for sessile serrated adenoma/polyps: SSA/Ps using image processing software analysis for Ki67 immunohistochemistry. Diagn Pathol. 2012; 7:59.

21. Choi KW, Jang BI, Eun JR, Lee JH, Bae YK, Kim TN. Expression of β-catenin, hMLH1, p53, Bcl-2, Bax and COX-2 in serrated adenomas of colon. Korean J Gastrointest Endosc. 2007; 34:19–27.

22. Bellizzi AM, Rock J, Marsh WL, Frankel WL. Serrated lesions of the appendix: a morphologic and immunohistochemical appraisal. Am J Clin Pathol. 2010; 133:623–632.

23. Fu B, Yachida S, Morgan R, Zhong Y, Montgomery EA, IacobuzioDonahue CA. Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am J Clin Pathol. 2012; 138:356–366.

24. Harvey NT, Ruszkiewicz A. Serrated neoplasia of the colorectum. World J Gastroenterol. 2007; 13:3792–3798.

25. Cunningham KS, Riddell RH. Serrated mucosal lesions of the colorectum. Curr Opin Gastroenterol. 2006; 22:48–53.

26. Krajewska M, Fenoglio-Preiser CM, Krajewski S, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol. 1996; 149:1449–1457.

27. Yao T, Kouzuki T, Kajiwara M, Matsui N, Oya M, Tsuneyoshi M. ‘Serrated' adenoma of the colorectum, with reference to its gastric differentiation and its malignant potential. J Pathol. 1999; 187:511–517.

28. Kim HJ, Kim TH, Lim BL, et al. Clinical Features of Colorectal Serrated Adenomas. J Korean Soc Coloproctol. 2006; 22:91–96.

29. Hawkins NJ, Bariol C, Ward RL. The serrated neoplasia pathway. Pathology. 2002; 34:548–555.

Go to :

Fig. 1.

Immunohistochemical staining of p53 in traditional serrated adenoma, hyperplastic polyp, and tubular adenoma. Intense nuclear staining of p53 is seen in traditional serrated adenoma (A, ×200) and tubular adenoma (C, ×200). However, p53 protein overexpression is not observed in hyperplastic polyp (B, ×200).

undefined

Fig. 2.

Immunohistochemical staining of Bcl-2 in traditional serrated adenoma, hyperplastic polyp, and tubular adenoma. Traditional serrated adenoma (A, ×200) and hyperplastic polyp (B, ×200) show loss of Bcl-2 expression. Tubular adenoma (C, ×200) shows cytoplasmic immunoreactivity for Bcl-2. Small lymphocytes in the lamina propria are internal control of Bcl-2 immunostaining.

undefined

Fig. 3.

Immunohistochemical staining of Ki-67 in traditional serrated adenoma, hyperplastic polyp, and tubular adenoma. Ki-67 positive cells (brown color) are seen at the bottom and on the surface of individual crypts of traditional serrated adenoma (A, ×200), hyperplastic polyp (B, ×200), and tubular adenoma (C, ×200).

undefined

Fig. 4.

Receiver operating characteristic analysis of Ki-67 level to identify traditional serrated adenomas. Area under the curve (AUC) was 0.808 (95% CI, 0.672–0.943) with cutoff point of 6%. Sensitivity=65%, specificity=80%.

undefined

Table 1.

Clinicopathologic Features of Patients with Traditional Serrated Adenomas, Tubular Adenomas, and Hyperplastic Polyps

Feature	Traditional serrated adenomas (n=20)	Hyperplastic polyps (n=20)	p-value	Tubular adenomas (n=20)	p-value
Age (yr)	59.4±11.5	65.9±12.2	0.091	62.1±8.1	0.397
Sex			＜1.000		＜1.000
Male	12 (60.0)	13 (65.0)		11 (55.0)
Female	8 (40.0)	7 (35.0)		9 (45.0)
Location			＜1.000		0.301
Proximal	4 (20.0)	4 (20.0)		8 (40.0)
Distal	16 (80.0)	16 (80.0)		12 (60.0)
Size (cm)	1.13±0.32	1.06±0.21	0.514	1.07±0.18	＜1.000
≤1	11 (55.0)	14 (70.0)		10 (50.0)
＞1	9 (45.0)	6 (30.0)		10 (50.0)

Values are presented as mean±SD or n (%).

Table 2.

Expressions of p53, Bcl-2, Ki-67 in Patients with Traditional Serrated Adenomas, Tubular Adenomas, and Hyperplastic Polyps

	Traditional serrated adenomas (n=20)	0) Hyperplastic polyps (n=20)	20) p-value Tu	ubular adenomas (n=2	0) p-value
p53 expression			0.487		＜1.000
Positive	2 (10.0)	0 (0)		3 (15.0)
Negative	18 (90.0)	20 (100.0)		17 (85.0)
Bcl-2 expression			0.342		0.001
Positive	4 (20.0)	1 (5.0)		15 (75.0)
Negative	16 (80.0)	19 (95.0)		5 (25.0)
Ki-67 labeling index (%)	14.85±12.45	4.45±3.43	0.001	16.15±16.84	0.783

Values are presented as n (%) or mean±SD.

Table 3.

Relationship between Clinicopathological Features and Expressions of p53, Bcl-2, Ki-67 in Traditional Serrated Adenomas

	n (%)	p53	p-value	Bcl-2	p-value	Ki-67 labeling index (%)	p-value
Age (yr)			0.495		0.619		0.483
＜60	12 (60.0)	2 (10.0)		3 (15.0)		16.50±12.44
≥60	8 (40.0)	0 (0)		1 (5.0)		12.38±12.87
Sex			0.495		0.619		0.667
Male	12 (60.0)	2 (10.0)		3 (15.0)		13.83±12.09
Female	8 (40.0)	0 (0)		1 (5.0)		16.38±13.65
Location			＜1.000		0.538		0.261
Proximal	4 (20.0)	0 (0)		0 (0)		21.25±14.36
Distal	16 (80.0)	2 (10.0)		4 (20.0)		13.25±11.89
Size (cm)			0.479		0.591		0.120
≤1	11 (55.0)	2 (10.0)		3 (15.0)		10.91±8.64
＞1	9 (45.0)	0 (0)		1 (5.0)		19.67±15.07

Values are presented as n (%) or mean±SD.

Table 4.

Expressions of p53, Bcl-2, Ki-67 in Traditional Serrated Adenomas with Low and High Grade Dysplasia

	TSALD (n=12) TSAHD (n=8)	p-value
p53 expression		0.147
Positive	2 (25.0)0 (0)
Negative	6 (75.0)12 (100.0)
Bcl-2 expression		0.014
Positive	4 (50.0)0 (0)
Negative	4 (50.0)12 (100.0)
Ki-67 labeling index (%)	12.83±10.50 17.88±15.16	0.389

Values are presented as n (%) or mean±SD. TSALD, traditional serrated adenomas with low grade dysplasia; TSAHD, traditional serrated adenomas with high grade dysplasia.

Table 5.

Expressions of p53, Bcl-2, Ki-67 in Tubular Adenomas with Low and High Grade Dysplasia

	TALD (n=10)	TAHD (n=10)	p-value
p53 expression			0.211
Positive	0 (0)	3 (30.0)
Negative	10 (100.0)	7 (70.0)
Bcl-2 expression			＜1.000
Positive	7 (70.0)	8 (80.0)
Negative	3 (30.0)	2 (20.0)
Ki-67 labeling index	(%) 9.30±11.26	23.00±19.18	0.067

TALD, tubular adenomas with low grade dysplasia; TAHD, tubular adenomas with high grade dysplasia.

TOOLS

Similar articles